Ribavirin. Red Book Committee recommendations questioned

The new guidelines provided by the Committee on Infectious Diseases of the American Academy of Pediatrics on the Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection (RSV) are perplexing and prompt concern: "Ribavirin treatment is recommended for the following patients hos...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 1994-04, Vol.93 (4), p.672-673
Main Authors: Wald, E R, Dashefsky, B
Format: Article
Language:English
Subjects:
Drug therapy
Health aspects
Humans
Infant
Pediatric respiratory diseases
Pediatrics
Practice Guidelines as Topic
Prescription drugs
Regulation
Respiratory Syncytial Virus Infections - drug therapy
Respiratory Tract Infections - drug therapy
Respiratory Tract Infections - microbiology
Ribavirin
Ribavirin - therapeutic use
Societies, Medical
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The new guidelines provided by the Committee on Infectious Diseases of the American Academy of Pediatrics on the Use of Ribavirin in the Treatment of Respiratory Syncytial Virus Infection (RSV) are perplexing and prompt concern: "Ribavirin treatment is recommended for the following patients hospitalized with RSV lower respiratory tract disease: a. infants at high risk for severe or complicated RSV infection, including those with complicated congenital heart disease (including pulmonary hypertension); those with bronchopulmonary dysplasia, . . ."1,pp502-503 The accompanying qualifier that "the recommendations in this statement do not indicate an exclusive course of treatment or procedure to be followed"1,p501 is important but insufficient to dampen the effect of the Committee's decision to change its former stance of merely urging consideration of the use of ribavirin for patients at high risk for complications2 to an unequivocal recommendation to do so.
ISSN:0031-4005
1098-4275
DOI:10.1542/peds.93.4.672